We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dyax and Serono Announces Agreements for Discovery of Therapeutic Antibodies
News

Dyax and Serono Announces Agreements for Discovery of Therapeutic Antibodies

Dyax and Serono Announces Agreements for Discovery of Therapeutic Antibodies
News

Dyax and Serono Announces Agreements for Discovery of Therapeutic Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dyax and Serono Announces Agreements for Discovery of Therapeutic Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dyax Corp. has announced that it has granted a non-exclusive license to its proprietary antibody phage display libraries to Serono for the discovery and development of therapeutic antibodies.

In addition, Dyax will perform funded research on certain targets of Serono to identify therapeutic antibodies.

Under the terms of the agreement, Dyax receives technology license fees and full-time employee payments from Serono for the funded research, as well as clinical milestone payments and royalties on net sales of any products that may result from Serono's development and commercialization of antibodies from Dyax's libraries.

The agreements also provide Serono with sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.

Henry E. Blair, Chairman and Chief Executive Officer of Dyax commented, "We are very excited to have entered into an agreement with Serono, one of the world's leading biotechnology companies."

"Dyax's collaborations with many of the top biotechnology companies demonstrate the industry's acknowledgement of our capabilities in protein-based therapeutics."

Mr. Blair continued, "We believe Dyax's technology will prove to be beneficial in expanding Serono's pipeline of product candidates."

Advertisement